281 related articles for article (PubMed ID: 10845674)
1. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
Tomita T; Yokosuka O; Tagawa M; Saisho H; Tamura S; Fukuda I; Omata M
J Hepatol; 2000 May; 32(5):850-8. PubMed ID: 10845674
[TBL] [Abstract][Full Text] [Related]
2. [Experimental study on the effect of combination therapy with lamivudine and famciclovir against duck hepatitis B virus in vivo].
Chen Y; Guo S; Qi Z; Huang A
Zhonghua Gan Zang Bing Za Zhi; 2001 Aug; 9(4):209-11. PubMed ID: 11602049
[TBL] [Abstract][Full Text] [Related]
3. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
[TBL] [Abstract][Full Text] [Related]
4. Experimental study on pathogenicity of precore mutants in Hepadnaviridae.
Ma Z; Wen Y; Xiong S; Zhai W; He L; Yao X
Chin Med J (Engl); 1998 Jun; 111(6):519-23. PubMed ID: 11245071
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
7. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
8. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections.
Zhang YY; Summers J
J Virol; 1999 May; 73(5):3616-22. PubMed ID: 10196253
[TBL] [Abstract][Full Text] [Related]
9. Duck hepatitis B virus replication in primary bile duct epithelial cells.
Lee JY; Culvenor JG; Angus P; Smallwood R; Nicoll A; Locarnini S
J Virol; 2001 Aug; 75(16):7651-61. PubMed ID: 11462037
[TBL] [Abstract][Full Text] [Related]
10. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.
Luscombe C; Pedersen J; Bowden S; Locarnini S
Liver; 1994 Aug; 14(4):182-92. PubMed ID: 7968278
[TBL] [Abstract][Full Text] [Related]
11. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.
Tsiquaye KN; Slomka MJ; Maung M
J Med Virol; 1994 Mar; 42(3):306-10. PubMed ID: 8006644
[TBL] [Abstract][Full Text] [Related]
12. [Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B].
Chen XM; Liu ZM; Du XF; Yang ZG; Chen XM
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 34(2):121-5. PubMed ID: 15812884
[TBL] [Abstract][Full Text] [Related]
13. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
14. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Seignères B; Martin P; Werle B; Schorr O; Jamard C; Rimsky L; Trépo C; Zoulim F
Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
[TBL] [Abstract][Full Text] [Related]
15. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
Le Guerhier F; Pichoud C; Guerret S; Chevallier M; Jamard C; Hantz O; Li XY; Chen SH; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
[TBL] [Abstract][Full Text] [Related]
17. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo].
Chen X; Chen H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348
[TBL] [Abstract][Full Text] [Related]
19. Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo.
Li CQ; Zhu YT; Zhang FX; Fu LC; Li XH; Cheng Y; Li XY
World J Gastroenterol; 2005 Jan; 11(3):426-8. PubMed ID: 15637760
[TBL] [Abstract][Full Text] [Related]
20. Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure.
Barraud L; Guerret S; Chevallier M; Borel C; Jamard C; Trepo C; Wild CP; Cova L
Hepatology; 1999 Apr; 29(4):1317-23. PubMed ID: 10094981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
